289 related articles for article (PubMed ID: 24322529)
1. Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis.
Magge D; Zenati MS; Austin F; Mavanur A; Sathaiah M; Ramalingam L; Jones H; Zureikat AH; Holtzman M; Ahrendt S; Pingpank J; Zeh HJ; Bartlett DL; Choudry HA
Ann Surg Oncol; 2014 Apr; 21(4):1159-65. PubMed ID: 24322529
[TBL] [Abstract][Full Text] [Related]
2. Institutional learning curve of cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion for peritoneal malignancies.
Polanco PM; Ding Y; Knox JM; Ramalingam L; Jones H; Hogg ME; Zureikat AH; Holtzman MP; Pingpank J; Ahrendt S; Zeh HJ; Bartlett DL; Choudry HA
Ann Surg Oncol; 2015 May; 22(5):1673-9. PubMed ID: 25377640
[TBL] [Abstract][Full Text] [Related]
3. Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent or progressive diffuse malignant peritoneal mesothelioma: clinicopathologic characteristics and survival outcome.
Ihemelandu C; Bijelic L; Sugarbaker PH
Ann Surg Oncol; 2015 May; 22(5):1680-5. PubMed ID: 25120250
[TBL] [Abstract][Full Text] [Related]
4. Malignant Peritoneal Mesothelioma: National Practice Patterns, Outcomes, and Predictors of Survival.
Verma V; Sleightholm RL; Rusthoven CG; Koshy M; Sher DJ; Grover S; Simone CB
Ann Surg Oncol; 2018 Jul; 25(7):2018-2026. PubMed ID: 29721724
[TBL] [Abstract][Full Text] [Related]
5. The Role of Ki-67 and Pre-cytoreduction Parameters in Selecting Diffuse Malignant Peritoneal Mesothelioma (DMPM) Patients for Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Kusamura S; Torres Mesa PA; Cabras A; Baratti D; Deraco M
Ann Surg Oncol; 2016 May; 23(5):1468-73. PubMed ID: 26572754
[TBL] [Abstract][Full Text] [Related]
6. Impact of Combination Chemotherapy in Peritoneal Mesothelioma Hyperthermic Intraperitoneal Chemotherapy (HIPEC): The RENAPE Study.
Malgras B; Gayat E; Aoun O; Lo Dico R; Eveno C; Pautrat K; Delhorme JB; Passot G; Marchal F; Sgarbura O; Ferron G; Goéré D; Andre T; Pocard M;
Ann Surg Oncol; 2018 Oct; 25(11):3271-3279. PubMed ID: 29978366
[TBL] [Abstract][Full Text] [Related]
7. Preoperative Thrombocytosis Predicts Shortened Survival in Patients with Malignant Peritoneal Mesothelioma Undergoing Operative Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy.
Li YC; Khashab T; Terhune J; Eckert RL; Hanna N; Burke A; Richard Alexander H
Ann Surg Oncol; 2017 Aug; 24(8):2259-2265. PubMed ID: 28324285
[TBL] [Abstract][Full Text] [Related]
8. Is Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy Justified for Biphasic Variants of Peritoneal Mesothelioma? Outcomes from the Peritoneal Surface Oncology Group International Registry.
Votanopoulos KI; Sugarbaker P; Deraco M; Morris D; Glehen O; Elias D; De Simone M; Robella M; Heyd B; Kusamura S; Baratti D; Chouliaras K; Russell G; Shen P; Levine EA;
Ann Surg Oncol; 2018 Mar; 25(3):667-673. PubMed ID: 29260418
[TBL] [Abstract][Full Text] [Related]
9. Repeat cytoreductive surgery and heated intraperitoneal chemotherapy may offer survival benefit for intraperitoneal mesothelioma: a single institution experience.
Wong J; Koch AL; Deneve JL; Fulp W; Tanvetyanon T; Dessureault S
Ann Surg Oncol; 2014 May; 21(5):1480-6. PubMed ID: 24158467
[TBL] [Abstract][Full Text] [Related]
10. Aggressive locoregional surgical therapy for gastric peritoneal carcinomatosis.
Magge D; Zenati M; Mavanur A; Winer J; Ramalingam L; Jones H; Zureikat A; Holtzman M; Lee K; Ahrendt S; Pingpank J; Zeh HJ; Bartlett DL; Choudry HA
Ann Surg Oncol; 2014 May; 21(5):1448-55. PubMed ID: 24197761
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Mesothelioma: Experience of a Peritoneal Surface Malignancy Center.
Aydin N; Sardi A; Milovanov V; Nieroda C; Sittig M; Nunez MF; Jimenez W; Gushchin V
Am Surg; 2015 Dec; 81(12):1253-9. PubMed ID: 26736164
[TBL] [Abstract][Full Text] [Related]
12. Malignant peritoneal mesothelioma treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is GLUT1 expression a major prognostic factor? A preliminary study.
Hommell-Fontaine J; Isaac S; Passot G; Decullier E; Traverse-Glehen A; Cotte E; You B; Mohamed F; Gilly FN; Glehen O; Berger F
Ann Surg Oncol; 2013 Nov; 20(12):3892-8. PubMed ID: 23800898
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion in Patients with High-Grade, High-Volume Disseminated Mucinous Appendiceal Neoplasms.
Polanco PM; Ding Y; Knox JM; Ramalingam L; Jones H; Hogg ME; Zureikat AH; Holtzman MP; Pingpank J; Ahrendt S; Zeh HJ; Bartlett DL; Choudry HA
Ann Surg Oncol; 2016 Feb; 23(2):382-90. PubMed ID: 26429720
[TBL] [Abstract][Full Text] [Related]
14. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis.
Helm JH; Miura JT; Glenn JA; Marcus RK; Larrieux G; Jayakrishnan TT; Donahue AE; Gamblin TC; Turaga KK; Johnston FM
Ann Surg Oncol; 2015 May; 22(5):1686-93. PubMed ID: 25124472
[TBL] [Abstract][Full Text] [Related]
15. Repeat cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent diffuse malignant peritoneal mesothelioma.
Huang Y; Alzahrani NA; Liauw W; Morris DL
Eur J Surg Oncol; 2015 Oct; 41(10):1373-8. PubMed ID: 26227745
[TBL] [Abstract][Full Text] [Related]
16. The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Deraco M; Baratti D; Hutanu I; Bertuli R; Kusamura S
Ann Surg Oncol; 2013 Apr; 20(4):1093-100. PubMed ID: 23456386
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
[No Abstract] [Full Text] [Related]
18. Diffuse malignant peritoneal mesothelioma: Failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
Baratti D; Kusamura S; Cabras AD; Dileo P; Laterza B; Deraco M
Ann Surg Oncol; 2009 Feb; 16(2):463-72. PubMed ID: 19082859
[TBL] [Abstract][Full Text] [Related]
19. A novel nomogram for peritoneal mesothelioma predicts survival.
Schaub NP; Alimchandani M; Quezado M; Kalina P; Eberhardt JS; Hughes MS; Beresnev T; Hassan R; Bartlett DL; Libutti SK; Pingpank JF; Royal RE; Kammula US; Pandalai P; Phan GQ; Stojadinovic A; Rudloff U; Alexander HR; Avital I
Ann Surg Oncol; 2013 Feb; 20(2):555-61. PubMed ID: 23233234
[TBL] [Abstract][Full Text] [Related]
20. Conversion to Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma After Bidirectional Chemotherapy.
Le Roy F; Gelli M; Hollebecque A; Honoré C; Boige V; Dartigues P; Benhaim L; Malka D; Ducreux M; Elias D; Goéré D
Ann Surg Oncol; 2017 Nov; 24(12):3640-3646. PubMed ID: 28849389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]